Jan 17, 2020 - Lilly (LLY) offers to buy Dermira for $1.1 billion. AstraZeneca (AZN) and AbbVie (ABBV) provide pipeline updates.
Jan 17, 2020 - Novo Nordisk's (NVO) Ozempic gets FDA approval for reducing the risk of major adverse cardiovascular events in people with type II diabetes and established CVD.
Jan 24, 2020 - Johnson & Johnson (JNJ) receives the European Commission's (EC) nod to the line extension of Stelara to treat six to 11-year-old pediatric patients with moderate-to-severe plaque psoriasis.
Jan 28, 2020 - AVEO releases results from a phase Ib study on ficlatuzumab in combination with nab-paclitaxel and gemcitabine for treating advanced pancreatic cancer. Shares inch up.
Jan 29, 2020 - Let us take a look at five big drug/biotech companies due to release their quarterly results on Jan 30.
Jan 29, 2020 - The FDA accepts for review Alkermes' (ALKS) NDA for ALKS 3831 for the treatment of schizophrenia and bipolar I disorder and has set an action date of Nov 15, 2020.
Jan 30, 2020 - LLY earnings call for the period ending December 31, 2019.
Jan 31, 2020 - Bayer (BAYRY) files application to the FDA for the new formulation of nifurtimox to improve the body-weight adjusted dosing in pediatric Chagas patients.
Jan 31, 2020 - Reyvow is the first drug in an entirely new class of acute migraine treatments.
Jan 31, 2020 - Lilly (LLY), Pfizer (PFE) and Novartis (NVS) announce Q4 results.